{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T19:24:28Z","timestamp":1761765868088},"reference-count":47,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2015,2,1]],"date-time":"2015-02-01T00:00:00Z","timestamp":1422748800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,2,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Introduction<\/jats:title>\n                  <jats:p>The success of medical therapies for Peyronie's disease (PD) has not been optimal, possibly because many of them went directly to clinical application without sufficient preclinical scientific research. Previous studies revealed cellular and molecular pathways involved in the formation of the PD plaque and in particular the role of the myofibroblast.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Aims<\/jats:title>\n                  <jats:p>The current work aimed to determine under normal and fibrotic conditions what differentiates PD cells from tunica albuginea (TA) and corpora cavernosa (CC) cells by defining their global transcriptional signatures and testing in vivo whether PD cells can generate a PD-like plaque.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Human TA, PD, and CC cells were grown with transforming growth factor beta 1 (TGF\u03b21; TA+, PD+, CC+) or without it (TA\u2212, PD\u2212, CC\u2212) and assayed by (i) immunofluorescence, Western blot and RT-PCR for myofibroblast, smooth muscle cell and stem cell markers; (ii) collagen content; and (iii) DNA microarray analysis. The ability of PD+ cells to induce a PD-like plaque in an immuno-suppressed rat model was assessed by Masson trichrome and Picrosirius Red stainings.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Main Outcomes Measures<\/jats:title>\n                  <jats:p>Fibroproliferative features of PD cells and identification of related key genes as novel targets to reduce plaque size.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Upon TGF\u03b21stimulation, collagen levels were increased by myofibroblasts in the PD+ but not in the CC+ cells. The transcriptional signature of the PD\u2212 cells identified fibroproliferative, myogenic (myofibroblasts), inflammatory, and collagen turnover genes that differentiate them from TA\u2212 or CC\u2212 cells and respond to TGF\u03b21 with a PD+ fibrotic phenotype, by upregulation of IGF-1, ACTG2, MYF5, ACTC1, PSTN, COL III, MMP3, and others. The PD+ cells injected into the TA of the rat induce a PD-like plaque.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>This suggests a novel combination therapy to eliminate a PD plaque by targeting the identified genes to (i) improve collagenase action by stimulating endogenous metalloproteinases specific to key collagen types and (ii) counteract fibromatosis by inhibiting myofibroblast generation, proliferation, and\/or apoptosis.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1111\/jsm.12760","type":"journal-article","created":{"date-parts":[[2014,12,12]],"date-time":"2014-12-12T01:59:30Z","timestamp":1418349570000},"page":"313-327","source":"Crossref","is-referenced-by-count":22,"title":["The Transcriptional Signatures of Cells from the Human Peyronie's Disease Plaque and the Ability of These Cells to Generate a Plaque in a Rat Model Suggest Potential Therapeutic Targets"],"prefix":"10.1093","volume":"12","author":[{"given":"Robert A.","family":"Gelfand","sequence":"first","affiliation":[{"name":"Division of Urology , Torrance, CA , USA"},{"name":"Department of Surgery , Torrance, CA , USA"},{"name":"Los Angeles Biomedical Research Institute , Torrance, CA , USA"},{"name":"Harbor-UCLA Medical Center , Torrance, CA , USA"},{"name":"Division of Endocrinology , Los Angeles, CA , USA"},{"name":"Charles Drew University of Medicine and Science , Los Angeles, CA , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dolores","family":"Vernet","sequence":"additional","affiliation":[{"name":"Division of Urology , Torrance, CA , USA"},{"name":"Department of Surgery , Torrance, CA , USA"},{"name":"Los Angeles Biomedical Research Institute , Torrance, CA , USA"},{"name":"Harbor-UCLA Medical Center , Torrance, CA , USA"},{"name":"Division of Endocrinology , Los Angeles, CA , USA"},{"name":"Charles Drew University of Medicine and Science , Los Angeles, CA , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Istvan","family":"Kovanecz","sequence":"additional","affiliation":[{"name":"Division of Urology , Torrance, CA , USA"},{"name":"Department of Surgery , Torrance, CA , USA"},{"name":"Los Angeles Biomedical Research Institute , Torrance, CA , USA"},{"name":"Harbor-UCLA Medical Center , Torrance, CA , USA"},{"name":"Department of Urology , Los Angeles, CA , USA"},{"name":"David Geffen School of Medicine , Los Angeles, CA , USA"},{"name":"UCLA , Los Angeles, CA , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacob","family":"Rajfer","sequence":"additional","affiliation":[{"name":"Division of Urology , Torrance, CA , USA"},{"name":"Department of Surgery , Torrance, CA , USA"},{"name":"Los Angeles Biomedical Research Institute , Torrance, CA , USA"},{"name":"Harbor-UCLA Medical Center , Torrance, CA , USA"},{"name":"Department of Urology , Los Angeles, CA , USA"},{"name":"David Geffen School of Medicine , Los Angeles, CA , USA"},{"name":"UCLA , Los Angeles, CA , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nestor F.","family":"Gonzalez-Cadavid","sequence":"additional","affiliation":[{"name":"Division of Urology , Torrance, CA , USA"},{"name":"Department of Surgery , Torrance, CA , USA"},{"name":"Los Angeles Biomedical Research Institute , Torrance, CA , USA"},{"name":"Harbor-UCLA Medical Center , Torrance, CA , USA"},{"name":"Division of Endocrinology , Los Angeles, CA , USA"},{"name":"Charles Drew University of Medicine and Science , Los Angeles, CA , USA"},{"name":"Department of Urology , Los Angeles, CA , USA"},{"name":"David Geffen School of Medicine , Los Angeles, CA , USA"},{"name":"UCLA , Los Angeles, CA , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2015,2,1]]},"reference":[{"key":"2023012309023255300_bb0010","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1517\/14656566.2011.544252","article-title":"Current status and new developments in Peyronie's disease: Medical, minimally invasive and surgical treatment options","volume":"12","author":"Gur","year":"2011","journal-title":"Expert Opin Pharmacother"},{"key":"2023012309023255300_bb0015","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1111\/j.1743-6109.2010.01850.x","article-title":"The management of Peyronie's disease: Evidence-based 2010 guidelines","volume":"7","author":"Ralph","year":"2010","journal-title":"J Sex Med"},{"key":"2023012309023255300_bb0020","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1016\/j.juro.2012.01.032","article-title":"Phase 2b study of the clinical efficacy and safety of collagenase Clostridium histolyticum in patients with Peyronie disease","volume":"187","author":"Gelbard","year":"2012","journal-title":"J Urol"},{"key":"2023012309023255300_bb0025","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.juro.2013.01.087","article-title":"Clinical efficacy, safety and tolerability of collagenase clostridium histolyticum for the treatment of Peyronie disease in 2 large double-blind, randomized, placebo controlled phase 3 studies","volume":"190","author":"Gelbard","year":"2013","journal-title":"J Urol"},{"key":"2023012309023255300_bb0030","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/nrurol.2010.24","article-title":"Treatment of Peyronie's disease with PDE5 inhibitors: an antifibrotic strategy","volume":"7","author":"Gonzalez-Cadavid","year":"2010","journal-title":"Nat Rev Urol"},{"key":"2023012309023255300_bb0035","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/j.1743-6109.2008.01104.x","article-title":"Experimental models of Peyronie's disease. Implications for new therapies","volume":"6","author":"Gonzalez-Cadavid","year":"2009","journal-title":"J Sex Med"},{"key":"2023012309023255300_bb0040","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/S0022-5347(01)65361-8","article-title":"Proposal: Trauma as the cause of the Peyronie's lesion","volume":"157","author":"Devine","year":"1997","journal-title":"J Urol"},{"key":"2023012309023255300_bb0045","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1046\/j.1464-410X.2003.04224.x","article-title":"Fibrin as an inducer of fibrosis in the tunica albuginea of the rat: A new animal model of Peyronie's disease","volume":"91","author":"Davila","year":"2003","journal-title":"BJU Int"},{"key":"2023012309023255300_bb0050","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/S0022-5347(01)65368-0","article-title":"Scar contracture: Cellular and connective tissue aspects in Peyronie's disease","volume":"157","author":"Ehrlich","year":"1997","journal-title":"J Urol"},{"key":"2023012309023255300_bb0055","doi-asserted-by":"crossref","first-page":"3121","DOI":"10.1111\/jsm.12334","article-title":"Peyronie's disease plaque calcification\u2014Prevalence, time to identification, and development of a new grading classification","volume":"10","author":"Levine","year":"2013","journal-title":"J Sex Med"},{"key":"2023012309023255300_bb0060","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S0090-4295(01)01578-3","article-title":"Gene expression profiles in the Peyronie's disease plaque","volume":"59","author":"Magee","year":"2002","journal-title":"Urology"},{"key":"2023012309023255300_bb0065","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1038\/sj.ijir.3900873","article-title":"Gene expression in Peyronie's disease","volume":"14","author":"Gonzalez-Cadavid","year":"2002","journal-title":"Int J Impot Res"},{"key":"2023012309023255300_bb0070","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.urology.2004.04.006","article-title":"Comparison of gene expression profiles between Peyronie's disease and Dupuytren's contracture","volume":"64","author":"Qian","year":"2004","journal-title":"Urology"},{"key":"2023012309023255300_bb0075","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/S1089-8603(02)00124-6","article-title":"Effect of nitric oxide on the differentiation of fibroblasts into myofibroblasts in the Peyronie's fibrotic plaque and in its rat model","volume":"7","author":"Vernet","year":"2002","journal-title":"Nitric Oxide"},{"key":"2023012309023255300_bb0080","doi-asserted-by":"crossref","first-page":"8785","DOI":"10.1074\/jbc.R113.451211","article-title":"Interstitial collagen catabolism","volume":"288","author":"Fields","year":"2013","journal-title":"J Biol Chem"},{"key":"2023012309023255300_bb0085","doi-asserted-by":"crossref","first-page":"L709","DOI":"10.1152\/ajplung.00418.2012","article-title":"Always cleave up your mess: Targeting collagen degradation to treat tissue fibrosis","volume":"304","author":"McKleroy","year":"2013","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"2023012309023255300_bb0090","first-page":"209","article-title":"Matrix metalloproteinase inhibitors as investigative tools in the pathogenesis and management of vascular disease","volume":"103","author":"Benjamin","year":"2012","journal-title":"EXS"},{"key":"2023012309023255300_bb0095","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1111\/j.1476-5381.2010.01149.x","article-title":"Sildenafil, a phosphodiesterase type 5 inhibitor, attenuates diabetic nephropathy in non-insulin-dependent Otsuka Long-Evans Tokushima Fatty rats","volume":"162","author":"Kuno","year":"2011","journal-title":"Br J Pharmacol"},{"key":"2023012309023255300_bb0100","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1095\/biolreprod.105.041038","article-title":"Evidence that osteogenic progenitor cells in the human tunica albuginea may originate from stem cells: implications for peyronie disease","volume":"73","author":"Vernet","year":"2005","journal-title":"Biol Reprod"},{"key":"2023012309023255300_bb0105","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1111\/j.1743-6109.2005.00197.x","article-title":"Phosphodiesterase type 5 is not upregulated by tadalafil in cultures of human penile cells","volume":"3","author":"Vernet","year":"2006","journal-title":"J Sex Med"},{"key":"2023012309023255300_bb0110","doi-asserted-by":"publisher","first-page":"e31430","DOI":"10.1371\/journal.pone.0031430","article-title":"In vitro study of novel collagenase (XIAFLEX\u00ae) on Dupuytren's disease fibroblasts displays unique drug related properties","volume":"7","author":"Syed","year":"2012","journal-title":"PLoS ONE"},{"key":"2023012309023255300_bb0115","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1111\/j.1464-410X.2006.05955.x","article-title":"Effects of long-term vardenafil treatment on the development of fibrotic plaques in a rat model of Peyronie's disease","volume":"97","author":"Ferrini","year":"2006","journal-title":"BJU Int"},{"key":"2023012309023255300_bb0120","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1186\/1479-5876-10-159","article-title":"Effects of sildenafil and\/or muscle derived stem cells on myocardial infarction","volume":"10","author":"Wang","year":"2012","journal-title":"J Transl Med"},{"key":"2023012309023255300_bb0125","doi-asserted-by":"crossref","first-page":"2952","DOI":"10.1111\/jsm.12336","article-title":"Chronic High Dose Intraperitoneal Bisphenol A (BPA) induces substantial histological and gene expression alterations in rat penile tissue without impairing erectile function","volume":"10","author":"Kovanecz","year":"2013","journal-title":"J Sex Med"},{"key":"2023012309023255300_bb0130","doi-asserted-by":"crossref","first-page":"4294","DOI":"10.1111\/febs.12253","article-title":"Mechanisms regulating skeletal muscle growth and atrophy","volume":"280","author":"Schiaffino","year":"2013","journal-title":"FEBS J"},{"key":"2023012309023255300_bb0135","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1095\/biolreprod.104.030833","article-title":"Gene transfer of inducible nitric oxide synthase complementary DNA regresses the fibrotic plaque in an animal model of Peyronie's disease","volume":"71","author":"Davila","year":"2004","journal-title":"Biol Reprod"},{"key":"2023012309023255300_bb0140","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1111\/j.1743-6109.2007.00459.x","article-title":"Antisense and short hairpin RNA (shRNA) constructs targeting PIN (Protein Inhibitor of NOS) ameliorate aging-related erectile dysfunction in the rat","volume":"4","author":"Magee","year":"2007","journal-title":"J Sex Med"},{"key":"2023012309023255300_bb0145","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1097\/MNH.0b013e328335f91f","article-title":"Endothelin, hypertension and chronic kidney disease: new insights","volume":"19","author":"Kohan","year":"2010","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"2023012309023255300_bb0150","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1161\/01.RES.0000249379.55535.21","article-title":"Vascular calcification: Pathobiological mechanisms and clinical implications","volume":"99","author":"Johnson","year":"2006","journal-title":"Circ Res"},{"key":"2023012309023255300_bb0155","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.mad.2004.09.023","article-title":"Profiling molecular targets of TGF-beta1 in prostate fibroblast-to myofibroblast transdifferentiation","volume":"126","author":"Untergasser","year":"2005","journal-title":"Mech Ageing Dev"},{"key":"2023012309023255300_bb0160","doi-asserted-by":"crossref","first-page":"4117","DOI":"10.1007\/s00018-013-1330-4","article-title":"Skeletal muscle hypertrophy and regeneration: Interplay between the myogenic regulatory factors (MRFs) and insulin-like growth factors (IGFs) pathways","volume":"70","author":"Zanou","year":"2013","journal-title":"Cell Mol Life Sci"},{"issue":"Pt 1","key":"2023012309023255300_bb0165","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1242\/jcs.087841","article-title":"Periostin modulates myofibroblast differentiation during full-thickness cutaneous wound repair","volume":"125","author":"Elliott","year":"2012","journal-title":"J Cell Sci"},{"key":"2023012309023255300_bb0170","doi-asserted-by":"crossref","first-page":"3574","DOI":"10.1016\/j.yexcr.2009.07.015","article-title":"Periostin differentially induces proliferation, contraction and apoptosis of primary Dupuytren's disease and adjacent palmar fascia cells","volume":"315","author":"Vi","year":"2009","journal-title":"Exp Cell Res"},{"key":"2023012309023255300_bb0175","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1186\/1465\u20139921-11\u201385","article-title":"Bone morphogenetic protein (BMP)-4 and BMP-7 regulate differentially transforming growth factor (TGF)-beta1 in normal human lung fibroblasts (NHLF)","volume":"11","author":"Pegorier","year":"2010","journal-title":"Respir Res"},{"key":"2023012309023255300_bb0180","doi-asserted-by":"publisher","first-page":"e83446","DOI":"10.1371\/journal.pone.0083446","article-title":"Polymorphism in the alpha cardiac muscle actin 1 gene is associated to susceptibility to chronic inflammatory cardiomyopathy","volume":"8","author":"Frade","year":"2013","journal-title":"PLoS ONE"},{"key":"2023012309023255300_bb0185","doi-asserted-by":"crossref","first-page":"3934","DOI":"10.1016\/j.biomaterials.2014.01.028","article-title":"The effects of actin cytoskeleton perturbation on keratin intermediate filament formation in mesenchymal stem\/stromal cells","volume":"35","author":"Chang","year":"2014","journal-title":"Biomaterials"},{"key":"2023012309023255300_bb0190","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1007\/s00198-011-1892-7","article-title":"The multiple facets of periostin in bone metabolism","volume":"23","author":"Merle","year":"2012","journal-title":"Osteoporos Int"},{"key":"2023012309023255300_bb0195","doi-asserted-by":"crossref","first-page":"3574","DOI":"10.1016\/j.yexcr.2009.07.015","article-title":"Periostin differentially induces proliferation, contraction and apoptosis of primary Dupuytren's disease and adjacent palmar fascia cells","volume":"315","author":"Vi","year":"2009","journal-title":"Exp Cell Res"},{"key":"2023012309023255300_bb0200","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1038\/sj.ijir.3901170","article-title":"Chromosomal instability is demonstrated by fibroblasts derived from the tunica of men with Peyronie's disease","volume":"16","author":"Mulhall","year":"2004","journal-title":"Int J Impot Res"},{"key":"2023012309023255300_bb0205","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/sj.ijir.3901183","article-title":"Peyronie's disease fibroblasts demonstrate tumorigenicity in the severe combined immunodeficient (SCID) mouse model","volume":"16","author":"Mulhall","year":"2004","journal-title":"Int J Impot Res"},{"key":"2023012309023255300_bb0210","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1210\/me.2010-0340","article-title":"ROS signaling by NOX4 drives fibroblast-to-myofibroblast differentiation in the diseased prostatic stroma","volume":"25","author":"Sampson","year":"2011","journal-title":"Mol Endocrinol"},{"key":"2023012309023255300_bb0215","doi-asserted-by":"crossref","first-page":"2586","DOI":"10.1210\/en.2012-2259","article-title":"Stromal insulin-like growth factor binding protein 3 (IGFBP3) is elevated in the diseased human prostate and promotes ex vivo fibroblast-to-myofibroblast differentiation","volume":"154","author":"Sampson","year":"2013","journal-title":"Endocrinology"},{"key":"2023012309023255300_bb0220","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1159\/000341470","article-title":"Microarray analysis of Dupuytren's disease cells: the profibrogenic role of the TGF-\u03b2 inducible p38 MAPK pathway","volume":"30","author":"Ratkaj","year":"2012","journal-title":"Cell Physiol Biochem"},{"key":"2023012309023255300_bb0225","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.matbio.2010.06.007","article-title":"Modulatory effect of interleukin-1\u03b1 on expression of structural matrix proteins, MMPs and TIMPs in human cardiac myofibroblasts: role of p38 MAP kinase","volume":"29","author":"Turner","year":"2010","journal-title":"Matrix Biol"},{"key":"2023012309023255300_bb0230","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1111\/j.2047-2927.2013.00181.x","article-title":"Adipose tissue-derived stem cell therapy for prevention and treatment of erectile dysfunction in a rat model of Peyronie's disease","volume":"2","author":"Gokce","year":"2014","journal-title":"Andrology"},{"key":"2023012309023255300_bb0235","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1016\/j.ajpath.2011.01.035","article-title":"The early growth response gene Egr2 (Alias Krox20) is a novel transcriptional target of transforming growth factor-\u03b2 that is up-regulated in systemic sclerosis and mediates profibrotic responses","volume":"178","author":"Fang","year":"2011","journal-title":"Am J Pathol"},{"key":"2023012309023255300_bb0240","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1097\/01.pap.0000131773.16130.aa","article-title":"Myofibroblastic malignancies","volume":"11","author":"Fisher","year":"2004","journal-title":"Adv Anat Pathol"}],"container-title":["The Journal of Sexual Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1743609515309279?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1743609515309279?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jsm\/article-pdf\/12\/2\/313\/48625102\/jsm_12_2_313.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jsm\/article-pdf\/12\/2\/313\/48625102\/jsm_12_2_313.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,23]],"date-time":"2023-01-23T09:24:47Z","timestamp":1674465887000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jsm\/article\/12\/2\/313\/6980227"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2,1]]},"references-count":47,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2015,2,1]]},"published-print":{"date-parts":[[2015,2,1]]}},"URL":"https:\/\/doi.org\/10.1111\/jsm.12760","relation":{},"ISSN":["1743-6109","1743-6095"],"issn-type":[{"value":"1743-6109","type":"electronic"},{"value":"1743-6095","type":"print"}],"subject":[],"published-other":{"date-parts":[[2015,2]]},"published":{"date-parts":[[2015,2,1]]}}}